GNPX (Genprex, Inc. Common Stock) Stock Analysis - News
Genprex, Inc. Common Stock (GNPX) is a publicly traded Healthcare sector company. As of May 20, 2026, GNPX trades at $0.79 with a market cap of $8.39M and a P/E ratio of -0.04. GNPX moved -1.47% today. Year to date, GNPX is -56.12%; over the trailing twelve months it is -94.52%. Its 52-week range spans $0.74 to $198.50. Rallies surfaces GNPX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in GNPX news today?
Genprex Partners with MD Anderson to Study TROP2, PTEN Biomarkers for Reqorsa Trials: Genprex has signed a Sponsored Research Agreement with UT MD Anderson to study biomarkers TROP2 and PTEN that may predict patient response to its lead gene therapy candidate, Reqorsa, in non-small cell and small cell lung cancer. Preclinical data indicate these markers could refine patient selection in its Acclaim-1 and Acclaim-3 trials.
LONGNECKER BRENT M sold 8 (~$9.84) on Apr 14, 2026.
LONGNECKER BRENT M sold 10 (~$12.3) on Apr 14, 2026.
Varner John Rodney bought 19.00K (~$20.05K) on Apr 21, 2023.
GNPX Analyst Consensus
GNPX analyst coverage data. Average price target: $0.00.
Common questions about GNPX
What changed in GNPX news today?
Genprex Partners with MD Anderson to Study TROP2, PTEN Biomarkers for Reqorsa Trials: Genprex has signed a Sponsored Research Agreement with UT MD Anderson to study biomarkers TROP2 and PTEN that may predict patient response to its lead gene therapy candidate, Reqorsa, in non-small cell and small cell lung cancer. Preclinical data indicate these markers could refine patient selection in its Acclaim-1 and Acclaim-3 trials.
Does Rallies summarize GNPX news?
Yes. Rallies summarizes GNPX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is GNPX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for GNPX. It does not provide personalized investment advice.
